Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.
anti-programmed death-1
complete response
immunotherapy
melanoma
outcomes
treatment discontinuation
Journal
Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
07
05
2023
received:
27
11
2022
accepted:
10
05
2023
medline:
23
8
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
ppublish
Résumé
Anti-programmed death-1 (anti-PD1) treatment has significantly improved outcomes of advanced melanoma with a considerable percentage of patients achieving complete response (CR). This real-world study analyzed the feasibility of elective anti-PD1 discontinuation in advanced melanoma patients with CR and evaluated factors related to sustained response. Thirty-five patients with advanced cutaneous or primary unknown melanoma with CR to nivolumab or pembrolizumab from 11 centers were included. Mean age was 66.5 years, and 97.1% had ECOG PS 0-1. 28.6% had ≥3 metastatic sites with 58.8% having M1a-M1b disease; 8.6% had liver and 5.7% had brain metastases. At baseline, 80% had normal LDH, and 85.7% had a neutrophil-to-lymphocyte ratio ≤3. 74.3% of patients had CR confirmed in PET-CT. Median duration of anti-PD1 was 23.4 months (range 1.3-50.5). 24 months after therapy discontinuation, 91.9% of patients were progression-free. Estimated PFS and OS at 36, 48, and 60 months from the start of anti-PD1 were 94.2%, 89.9%, 84.3%, and 97.1%, 93.3%, 93.3%, respectively. Antibiotics use after anti-PD1 discontinuation increased the odds of progression (OR 16.53 [95% CI 1.7, 226.03]). The study confirms the feasibility of elective anti-PD1 discontinuation in advanced melanoma patients with CR and favorable prognostic factors at baseline.
Substances chimiques
Antineoplastic Agents, Immunological
0
Nivolumab
31YO63LBSN
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
388-398Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
An, Y., Wu, Z., Wang, N., Yang, Z., Li, Y., Xu, B., & Sun, M. (2020). Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Journal of Translational Medicine, 18, 235. https://doi.org/10.1186/s12967-020-02404-x
Asher, N., Israeli-Weller, N., Shapira-Frommer, R., Ben-Betzalel, G., Schachter, J., Meirson, T., & Markel, G. (2021). Immunotherapy discontinuation in metastatic melanoma: Lessons from real-life clinical experience. Cancers, 13(12), 3074. https://doi.org/10.3390/CANCERS13123074
Bartlett, E. K., Flynn, J. R., Panageas, K. S., Ferraro, R. A., StaCruz, J. M., Postow, M. A., Coit, D. G., & Ariyan, C. E. (2020). High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer, 126, 76-85. https://doi.org/10.1002/cncr.32506
Bastholt, L., Schmidt, H., Kroll, J., Herrstedt, J., & Marie, I. (2019). ScienceDirect age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. European Journal of Cancer, 119, 122-131. https://doi.org/10.1016/j.ejca.2019.06.022
Ben-betzalel, G., Steinberg-silman, Y., Stoff, R., & Markel, G. (2019). ScienceDirect immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients. European Journal of Cancer, 108, 61-68. https://doi.org/10.1016/j.ejca.2018.12.012
Coen, O., Corrie, P., Marshall, H., Plummer, R., Ottensmeier, C., Hook, J., Bell, S., Sagoo, G. S., Meads, D., Bestall, J., Velikova, G., Gallagher, F. A., Smith, A., Howard, H., Mason, E., Katona, E., Silva, S., Collinson, M., Rodwell, S., & Danson, S. (2021). The DANTE trial protocol: A randomised phase III trial to evaluate the duration of ANti-PD-1 monoclonal antibody treatment in patients with metastatic melanoma. BMC Cancer, 21(1), 1-10. https://doi.org/10.1186/S12885-021-08509-W/FIGURES/1
Dimitriou, F., Zaremba, A., Allayous, C., Kähler, K. C., Gerard, C. L., Festino, L., Schäfer, S., Toussaint, F., Heinzerling, L., Hassel, J. C., Ascierto, P. A., Michielin, O., Hauschild, A., Lebbe, C., Livingstone, E., Ramelyte, E., Cheng, P. F., Dummer, R., & Mangana, J. (2021). Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. European Journal of Cancer, 149, 37-48. https://doi.org/10.1016/j.ejca.2021.02.037
Eun, Y., Kim, I. Y., Sun, J. M., Lee, J., Cha, H. S., Koh, E. M., Kim, H., & Lee, J. (2019). Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Scientific Reports, 9(1), 1-8. https://doi.org/10.1038/s41598-019-50574-6
Ferdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., Schadendorf, D., Fendler, W. P., & Livingstone, E. (2022). Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma. Cancer Imaging, 22(1), 1-8. https://doi.org/10.1186/s40644-022-00449-3
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., Dronca, R., Mitchell, T. C., Patnaik, A., Zarour, H. M., Joshua, A. M., Zhao, Q., Jensen, E., Ahsan, S., Ibrahim, N., & Ribas, A. (2019). Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of Oncology, 30(4), 582-588. https://doi.org/10.1093/annonc/mdz011
Hassel, J. C. (2019). 5-year results for pembrolizumab treatment of advanced melanoma. The Lancet Oncology, 20(9), 1187-1189. https://doi.org/10.1016/S1470-2045(19)30483-8
Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hill, A., Hogg, D., Marquez-Rodas, I., Jiang, J., Rizzo, J., Larkin, J., & Wolchok, J. D. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet Oncology, 19(11), 1480-1492. https://doi.org/10.1016/S1470-2045(18)30700-9
Jain, V., Hwang, W. T., Venigalla, S., Nead, K. T., Lukens, J. N., Mitchell, T. C., & Shabason, J. E. (2020). Association of age with efficacy of immunotherapy in metastatic melanoma. The Oncologist, 25(2), e381-e385. https://doi.org/10.1634/theoncologist.2019-0377
Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Geukes Foppen, M. H., Hoejberg, L., Schmidt, H., Van Thienen, J. V., Haanen, J. B. A. G., Tiainen, L., Svane, I. M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A. M., … Neyns, B. (2019). Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: Clinical outcomes in advanced melanoma. Annals of Oncology, 30(7), 1154-1161. https://doi.org/10.1093/annonc/mdz110
Jiang, S., Geng, S., Chen, Q., Zhang, C., Cheng, M., Yu, Y., Zhang, S., Shi, N., & Dong, M. (2022). Effects of concomitant antibiotics use on immune checkpoint inhibitor efficacy in cancer patients. Frontiers in Oncology, 12(February), 1-9. https://doi.org/10.3389/fonc.2022.823705
Kandel, M., Allayous, C., Dalle, S., Mortier, L., Dalac, S., Dutriaux, C., Leccia, M. T., Guillot, B., Saiag, P., Lacour, J. P., Legoupil, D., Lesimple, T., Aubin, F., Beylot-Barry, M., Brunet-Possenti, F., Arnault, J. P., Granel-Brocard, F., Stoebner, P. E., Dupuy, A., … Borget, I. (2018). Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. European Journal of Cancer, 105(August), 33-40. https://doi.org/10.1016/j.ejca.2018.09.026
Kartolo, A., Holstead, R., Khalid, S., Emack, J., Hopman, W., Robinson, A., & Baetz, T. (2020). Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy. Immunotherapy, 12(11), 785-798. https://doi.org/10.2217/IMT-2020-0105
Mulder, E. E. A. P., de Joode, K., Litière, S., ten Tije, A. J., Suijkerbuijk, K. P. M., Boers-Sonderen, M. J., Hospers, G. A. P., de Groot, J. W. B., van den Eertwegh, A. J. M., Aarts, M. J. B., Piersma, D., van Rijn, R. S., Kapiteijn, E., Vreugdenhil, G., van den Berkmortel, F. W. P. J., Hoop, E. O., de Franken, M. G., Ryll, B., Rutkowski, P., … van der Veldt, A. A. M. (2021). Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: The multicentre prospective safe stop trial. BMC Cancer, 21(1), 1-9. https://doi.org/10.1186/s12885-021-08018-w
Owen, C. N., Bai, X., Quah, T., Lo, S. N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I. L. M., Thompson, N., Vanella, V., Gerard, C. L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., … Menzies, A. M. (2021). Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Annals of Oncology, 32(7), 917-925. https://doi.org/10.1016/j.annonc.2021.03.204
Petrelli, F., Signorelli, D., Ghidini, M., Ghidini, A., Pizzutilo, E. G., Ruggieri, L., Cabiddu, M., Borgonovo, K., Dognini, G., Brighenti, M., De Toma, A., Rijavec, E., Garassino, M. C., Grossi, F., & Tomasello, G. (2020). Association of steroids use with survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Cancers, 12(3), 1-11. https://doi.org/10.3390/cancers12030546
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Rutkowski, P., Hassel, J. C., McNeil, C. M., Kalinka, E. A., Lebbé, C., Charles, J., Hernberg, M. M., Savage, K. J., Chiarion-Sileni, V., Mihalcioiu, C., Mauch, C., Arance, A., Cognetti, F., … Atkinson, V. (2020). Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. Journal of Clinical Oncology, 38(33), 3937-3946. https://doi.org/10.1200/JCO.20.00995
Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., Hwu, W. J., Weber, J. S., Gangadhar, T. C., Joseph, R. W., Dronca, R., Patnaik, A., Zarour, H., Kefford, R., Hersey, P., Zhang, J., Anderson, J., Diede, S. J., Ebbinghaus, S., & Hodi, F. S. (2018). Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. Journal of Clinical Oncology, 36(17), 1668-1674. https://doi.org/10.1200/JCO.2017.75.6270
Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., Larkin, J. M. G., Lorigan, P., Neyns, B., Blank, C. U., Petrella, T. M., Hamid, O., Su, S. C., Krepler, C., Ibrahim, N., & Long, G. V. (2019). Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The Lancet Oncology, 20(9), 1239-1251. https://doi.org/10.1016/S1470-2045(19)30388-2
Saiag, P., Mortier, L., Dutriaux, C., Benmahammed, L., Morsli, O., Train, C., Spampinato, A., Leccia, M. T., Meyer, N., & Grob, J. J. (2019). Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP). Annals of Oncology, 30, v549. https://doi.org/10.1093/annonc/mdz255.033
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C., Petrella, T. M., Hamid, O., Zhou, H., Ebbinghaus, S., Ibrahim, N., & Robert, C. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet, 390(10105), 1853-1862. https://doi.org/10.1016/S0140-6736(17)31601-X
Schank, T. E., Forschner, A., Sachse, M. M., Dimitrakopoulou-Strauss, A., Sachpekidis, C., Stenzinger, A., Volckmar, A. L., Enk, A., & Hassel, J. C. (2021). Complete metabolic response in FDG-PET-CT scan before discontinuation of immune checkpoint inhibitors correlates with long progression-free survival. Cancers, 13(11), 2616. https://doi.org/10.3390/cancers13112616
Tan, A. C., Emmett, L., Lo, S., Liu, V., Kapoor, R., Carlino, M. S., Guminski, A. D., Long, G. V., & Menzies, A. M. (2018). FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology, 29(10), 2115-2120. https://doi.org/10.1093/annonc/mdy330
Valentin, J., Ferté, T., Dorizy-Vuong, V., Dousset, L., Prey, S., Dutriaux, C., Pham-Ledard, A., Beylot-Barry, M., & Gérard, E. (2021). Real-world survival in patients with metastatic melanoma after discontinuation of anti-PD-1 immunotherapy for objective response or adverse effects: A retrospective study. Journal of Oncology, 2021, 1-8. https://doi.org/10.1155/2021/5524685
van Zeijl, M. C. T., van den Eertwegh, A. J. M., Wouters, M. W. J. M., de Wreede, L. C., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., ten Tije, A. J., van der Veldt, A. A. M., Vreugdenhil, G., van der Hoeven, J. J. M., & Haanen, J. B. A. G. (2022). Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice. International Journal of Cancer, 150(2), 317-326. https://doi.org/10.1002/ijc.33800
Warner, A. B., Palmer, J. S., Shoushtari, A. N., Goldman, D. A., Panageas, K. S., Hayes, S. A., Bajwa, R., Momtaz, P., Callahan, M. K., Wolchok, J. D., Postow, M. A., & Chapman, P. B. (2020). Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. Journal of Clinical Oncology, 38(15), 1655-1663. https://doi.org/10.1200/JCO.19.01464
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Butler, M. O., Hill, A., Márquez-Rodas, I., Haanen, J. B. A. G., Guidoboni, M., Maio, M., Schöffski, P., … Hodi, F. S. (2022). Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. Journal of Clinical Oncology, 40(2), 127-137. https://doi.org/10.1200/JCO.21.02229